High Blood MiR-802 Is Associated With Poor Prognosis in HCC Patients by Regulating DNA Damage Response 1 (REDD1)-Mediated Function of T Cells

Overview

Journal Oncol Res

Specialty Oncology

Date 2019 Apr 16

PMID 30982498

Citations 9

Authors

Chao Jiang

Xueyan Liu

Meng Wang

Guoyue Lv

Guangyi Wang

Affiliations

Soon will be listed here.

Abstract

miR-802 has been reported to be dysregulated in multiple tumors and contribute to tumor progression. However, its role in HCC was still largely unknown. The aim of this study is to investigate the function and mechanism of miR-802 in HCC progression. The results showed that miR-802 was upregulated in the peripheral blood and tumor tissue of HCC patients, and high levels of blood miR-802 predicted poor prognosis. miR-802 had no effect on the proliferation and migration of HCC cell lines. Interestingly, the levels of CD8/CD28 and regulated in development and DNA damage response 1 (REDD1) were declined along with the upregulation of miR-802 in vivo. Hence, it is speculated that miR-802 participated in the regulation of T-cell function in HCC patients. Furthermore, we demonstrated that mir-802 directly targets REDD1 and inhibited its expression. miR-802 increased the expression of programmed cell death protein 1 (PD-1) and decreased the expression of interferon-γ (IFN-γ) and CD8CD28 T-cell number. In conclusion, miR-802 was involved in T-cell exhaustion through posttranscriptionally suppressing REDD1, which might offer the suppressive effect of miR-802 on HCC progression.

Citing Articles

The crosstalking immune cells network creates a collective function beyond the function of each cellular constituent during the progression of hepatocellular carcinoma.

Koelsch N, Mirshahi F, Aqbi H, Saneshaw M, Idowu M, Olex A Sci Rep. 2023; 13(1):12630.

PMID: 37537225 PMC: 10400568. DOI: 10.1038/s41598-023-39020-w.

A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract.

Liao X, Li G, Cai R, Chen R Med Sci Monit. 2022; 28:e935348.

PMID: 35121724 PMC: 8826478. DOI: 10.12659/MSM.935348.

Dysfunction of miR-802 in tumors.

Gao T, Zou M, Shen T, Duan S J Clin Lab Anal. 2021; 35(11):e23989.

PMID: 34558723 PMC: 8605121. DOI: 10.1002/jcla.23989.

Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma.

Kunadirek P, Ariyachet C, Sriphoosanaphan S, Pinjaroen N, Sirichindakul P, Nookaew I Sci Rep. 2021; 11(1):11201.

PMID: 34045534 PMC: 8159962. DOI: 10.1038/s41598-021-90515-w.

Knockdown of miR-1275 protects against cardiomyocytes injury through promoting neuromedin U type 1 receptor.

Zeng Z, Ma H, Chen J, Huang N, Zhang Y, Su Y Cell Cycle. 2020; 19(24):3639-3649.

PMID: 33323026 PMC: 7781665. DOI: 10.1080/15384101.2020.1860310.

References

Kudo M . Immune Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer. 2016; 4(4):201-7. PMC: 4698623. DOI: 10.1159/000367758. View

Rudd C, Taylor A, Schneider H . CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009; 229(1):12-26. PMC: 4186963. DOI: 10.1111/j.1600-065X.2009.00770.x. View

Yuan C, Sun X, Zhu C, Liu S, Wu L, Chen H . Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells. Oncotarget. 2015; 6(31):32138-53. PMC: 4741664. DOI: 10.18632/oncotarget.5171. View

Reuschel E, Wang J, Shivers D, Muthumani K, Weiner D, Ma Z . REDD1 Is Essential for Optimal T Cell Proliferation and Survival. PLoS One. 2015; 10(8):e0136323. PMC: 4547781. DOI: 10.1371/journal.pone.0136323. View

Nishida N, Arizumi T, Hagiwara S, Ida H, Sakurai T, Kudo M . MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma. Liver Cancer. 2017; 6(2):113-125. PMC: 5340220. DOI: 10.1159/000449475. View

Sena L, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman D . Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity. 2013; 38(2):225-36. PMC: 3582741. DOI: 10.1016/j.immuni.2012.10.020. View

Hato T, Goyal L, Greten T, Duda D, Zhu A . Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology. 2014; 60(5):1776-82. PMC: 4211962. DOI: 10.1002/hep.27246. View

Wang B, Bao J, Wang J, Wang Y, Jiang M, Xing M . Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011; 17(28):3322-9. PMC: 3160536. DOI: 10.3748/wjg.v17.i28.3322. View

Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M . Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008; 14(10):3044-51. DOI: 10.1158/1078-0432.CCR-07-4079. View

10.

Dennis M, McGhee N, Jefferson L, Kimball S . Regulated in DNA damage and development 1 (REDD1) promotes cell survival during serum deprivation by sustaining repression of signaling through the mechanistic target of rapamycin in complex 1 (mTORC1). Cell Signal. 2013; 25(12):2709-16. PMC: 3867791. DOI: 10.1016/j.cellsig.2013.08.038. View

11.

Sun T, Yang Y, Luo X, Cheng Y, Zhang M, Wang K . Inhibition of tumor angiogenesis by interferon-γ by suppression of tumor-associated macrophage differentiation. Oncol Res. 2014; 21(5):227-35. DOI: 10.3727/096504014X13890370410285. View

12.

Horak P, Crawford A, Vadysirisack D, Nash Z, DeYoung M, Sgroi D . Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci U S A. 2010; 107(10):4675-80. PMC: 2842042. DOI: 10.1073/pnas.0907705107. View

13.

Ellisen L, Ramsayer K, Johannessen C, Yang A, Beppu H, Minda K . REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002; 10(5):995-1005. DOI: 10.1016/s1097-2765(02)00706-2. View

14.

Murray M, Gavile C, Nair J, Koorella C, Carlson L, Buac D . CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood. 2014; 123(24):3770-9. PMC: 4055924. DOI: 10.1182/blood-2013-10-530964. View

15.

Gao Q, Wang X, Qiu S, Yamato I, Sho M, Nakajima Y . Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15(3):971-9. DOI: 10.1158/1078-0432.CCR-08-1608. View

16.

Pinto J, Rolfo C, Raez L, Prado A, Araujo J, Bravo L . In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies. Sci Rep. 2017; 7(1):1526. PMC: 5431475. DOI: 10.1038/s41598-017-01207-3. View

17.

Tirado-Hurtado I, Fajardo W, Pinto J . DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer. Front Oncol. 2018; 8:106. PMC: 5906527. DOI: 10.3389/fonc.2018.00106. View

18.

Hao R, Su S, Wan Y, Shen F, Niu B, Coslo D . Bioinformatic analysis of microRNA networks following the activation of the constitutive androstane receptor (CAR) in mouse liver. Biochim Biophys Acta. 2016; 1859(9):1228-1237. PMC: 4975621. DOI: 10.1016/j.bbagrm.2016.04.002. View

19.

Singh A, Kumar R, Pandey A . Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers. Curr Chem Genom Transl Med. 2018; 12:9-26. PMC: 6047212. DOI: 10.2174/2213988501812010009. View

20.

Yuan F, Wang W . MicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1. Mol Med Rep. 2015; 12(3):4647-4651. DOI: 10.3892/mmr.2015.3921. View